Drug Trial Radar · NCT02669017
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
Last checked: Nov 20, 2026Latest source record: May 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
183
Actual
Start
Mar 2016
Primary completion
Feb 21, 2019
Study completion Feb 21, 2019
Sponsor
- Lead sponsor
- ADC Therapeutics S.A.Industry
- Sponsor type
- Industry
- First posted
- Jan 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1) and dose expansion (Part 2). In Part 2, participants will receive the dose level identified in Part 1.
Conditions
- Non-Hodgkin Lymphoma
- Burkitt's Lymphoma
- Chronic Lymphocytic Leukemia
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular
- Lymphoma, Mantle-Cell
- Lymphoma, Marginal Zone
- Waldenstrom Macroglobulinemia
- Primary Mediastinal B-cell Lymphoma
Interventions
ADCT-402Drug
intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)Time frame: Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)
- Recommended Dose of ADCT-402 for Part 2Time frame: Q3W schedule: Day 1 to End of Cycle 1 (3 weeks); Q6W schedule: Day 1 to End of Cycle 1 (6 weeks)
- Number of Participants Reporting at Least One Treatment Emergent Adverse Event (TEAE)Time frame: Day 1 to End of Study (a maximum of 18 months)
- Number of Participants Reporting at Least One Treatment Emergent Serious Adverse Event (SAE)Time frame: Day 1 to End of Study (a maximum of 18 months)
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
UC San Diego Moores Cancer Center
La Jolla, California
Winship Cancer Institute of Emory University
Atlanta, Georgia
Blood and Marrow Transplant Group of Georgia
Atlanta, Georgia
Washington University School of Medicine
St Louis, Missouri
Columbia University Medical Center Herbert Irving Pavilion
New York, New York
University Hospitals of Cleveland
Cleveland, Ohio
Greenville Health System, Institute for Translational Oncology Research, Clinical Research Unit
Greenville, South Carolina
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin
U.O Oncologia e Ematologia - Istituto Clinico Humanitas
Milan, Italy
University College London Hospitals
London, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.